RxDoctor Payments Data

Janie Ho, MD

Ophthalmology · Largo, FLNPI 1710961487

Payments from drug & device makers

$5,669in general payments, 2019–2025

Across 131 payments — averaging $43.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$1K
  • Mallinckrodt Hospital Products Inc.$903
  • Regeneron Healthcare Solutions, Inc.$741
  • AbbVie$464
  • Apellis Pharmaceuticals, Inc.$345
  • Regeneron$345
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$5,652100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,669 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$813,805
Medicare patients
459
Services billed
6,448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium27$10,352
Bromfenac Sodium50$9,915
LumiganBimatoprost13$9,761
RocklatanNetarsudil Mesylat/Latanoprost12$8,861
IlevroNepafenac12$8,417
Prednisolone Acetate83$4,281
Alphagan PBrimonidine Tartrate12$3,938
Loteprednol Etabonate11$1,599
Difluprednate13$1,291
Ketorolac Tromethamine34$912
Atropine Sulfate12$536
Brimonidine Tartrate40$456
Timolol Maleate39$437
Latanoprost37$403
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat37$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P$464$13,69925 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$253$11,95138 claims
NovartisIlevro$144$8,41712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →